中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2014年
2期
136-139
,共4页
陈欣%薛金红%张淑翼%孙丽莹%卢成志
陳訢%薛金紅%張淑翼%孫麗瑩%盧成誌
진흔%설금홍%장숙익%손려형%로성지
动脉粥样硬化%肝移植%受体,清道夫
動脈粥樣硬化%肝移植%受體,清道伕
동맥죽양경화%간이식%수체,청도부
Liver transplantation%Atherosclerosis%Scavenger receptor
目的 通过检测终末期肝病(ESLD)患者在肝移植术前后血巨噬细胞清道夫受体(SR)-B Ⅰ、CD36的表达,探讨ESLD行肝移植术后发生动脉粥样硬化的可能机制.方法 20例行肝移植术的患者,分别于术前及术后1年记录患者血压、血脂、血糖等临床资料,观察术后1年患者发生冠心病等临床事件的情况,用逆转录-聚合酶链式反应及Western blot测定肝移植术前及术后1年血浆SR-B Ⅰ及CD36表达水平变化.结果 与术前比较,肝移植患者术后1年的血总胆固醇[(5.34±0.87) mmol/L比(4.27±0.91) mmol/L]、甘油三酯[(2.47 ±0.81)mmol/L比(1.02±0.49) mmol/L]和低密度脂蛋白胆固醇水平[(3.36±0.67) mmol/L比(2.14±0.74) mmol/L]增高(P均＜0.05),HDL-C水平降低[(0.98 ±0.84) mmol/L比(1.58±0.34) mmol/L,P＜0.05].随访1年内,1例诊断为非ST段抬高型心肌梗死,行经皮冠状动脉介入治疗,1例诊断为心房颤动.术后1年,SR-BⅠmRNA(20.44±0.60比23.12 ±0.69,P＜0.05)和蛋白(0.21 ±0.13比0.64±0.28,P＜0.05)表达水平降低,CD36 mRNA(20.91±0.35比18.55 ±0.62,P＜0.05)和蛋白(0.94 ±0.13比0.42 ±0.19,P＜0.05)表达水平增高.结论 肝移植患者术后血SR-B Ⅰ表达水平较术前降低,CD36表达水平较术前增高,影响了肝移植术后脂类代谢,可能参与了动脉粥样硬化的发生和发展.
目的 通過檢測終末期肝病(ESLD)患者在肝移植術前後血巨噬細胞清道伕受體(SR)-B Ⅰ、CD36的錶達,探討ESLD行肝移植術後髮生動脈粥樣硬化的可能機製.方法 20例行肝移植術的患者,分彆于術前及術後1年記錄患者血壓、血脂、血糖等臨床資料,觀察術後1年患者髮生冠心病等臨床事件的情況,用逆轉錄-聚閤酶鏈式反應及Western blot測定肝移植術前及術後1年血漿SR-B Ⅰ及CD36錶達水平變化.結果 與術前比較,肝移植患者術後1年的血總膽固醇[(5.34±0.87) mmol/L比(4.27±0.91) mmol/L]、甘油三酯[(2.47 ±0.81)mmol/L比(1.02±0.49) mmol/L]和低密度脂蛋白膽固醇水平[(3.36±0.67) mmol/L比(2.14±0.74) mmol/L]增高(P均＜0.05),HDL-C水平降低[(0.98 ±0.84) mmol/L比(1.58±0.34) mmol/L,P＜0.05].隨訪1年內,1例診斷為非ST段抬高型心肌梗死,行經皮冠狀動脈介入治療,1例診斷為心房顫動.術後1年,SR-BⅠmRNA(20.44±0.60比23.12 ±0.69,P＜0.05)和蛋白(0.21 ±0.13比0.64±0.28,P＜0.05)錶達水平降低,CD36 mRNA(20.91±0.35比18.55 ±0.62,P＜0.05)和蛋白(0.94 ±0.13比0.42 ±0.19,P＜0.05)錶達水平增高.結論 肝移植患者術後血SR-B Ⅰ錶達水平較術前降低,CD36錶達水平較術前增高,影響瞭肝移植術後脂類代謝,可能參與瞭動脈粥樣硬化的髮生和髮展.
목적 통과검측종말기간병(ESLD)환자재간이식술전후혈거서세포청도부수체(SR)-B Ⅰ、CD36적표체,탐토ESLD행간이식술후발생동맥죽양경화적가능궤제.방법 20례행간이식술적환자,분별우술전급술후1년기록환자혈압、혈지、혈당등림상자료,관찰술후1년환자발생관심병등림상사건적정황,용역전록-취합매련식반응급Western blot측정간이식술전급술후1년혈장SR-B Ⅰ급CD36표체수평변화.결과 여술전비교,간이식환자술후1년적혈총담고순[(5.34±0.87) mmol/L비(4.27±0.91) mmol/L]、감유삼지[(2.47 ±0.81)mmol/L비(1.02±0.49) mmol/L]화저밀도지단백담고순수평[(3.36±0.67) mmol/L비(2.14±0.74) mmol/L]증고(P균＜0.05),HDL-C수평강저[(0.98 ±0.84) mmol/L비(1.58±0.34) mmol/L,P＜0.05].수방1년내,1례진단위비ST단태고형심기경사,행경피관상동맥개입치료,1례진단위심방전동.술후1년,SR-BⅠmRNA(20.44±0.60비23.12 ±0.69,P＜0.05)화단백(0.21 ±0.13비0.64±0.28,P＜0.05)표체수평강저,CD36 mRNA(20.91±0.35비18.55 ±0.62,P＜0.05)화단백(0.94 ±0.13비0.42 ±0.19,P＜0.05)표체수평증고.결론 간이식환자술후혈SR-B Ⅰ표체수평교술전강저,CD36표체수평교술전증고,영향료간이식술후지류대사,가능삼여료동맥죽양경화적발생화발전.
Objective To explore the association between expression changes of plasma macrophages scavenger receptor (SR)-B Ⅰ and CD36 and risk of arteriosclerosis in end-stage liver disease (ESLD) patients post liver transplantation.Methods A total of 20 liver transplantation patients were included.Clinical data including blood pressure,blood lipid,blood glucose,incidence of new-onset cardiovascular events were obtained.Plasma macrophages scavenger receptor SR-B Ⅰ and CD36 expressions were detected by polymerase chain reaction (RT-PCR) and Western-blot before and at 1 year after liver transplantation.Results The serum levels of TC [(5.34 ± 0.87) mmol/L vs.(4.27 ± 0.91) mmol/L],TG [(2.47±0.81)mmol/Lvs.(1.02±0.49)mmol/L] and LDL-C [(3.36±0.67)mmol/Lvs.(2.14± 0.74) mmol/L] were significantly increased (P ＜ 0.05) while the serum level of HDL-C [(0.98 ± 0.84) mmol/L vs.(1.58 ± 0.34) mmol/L] was significantly reduced (P ＜ 0.05) at 1 year post transplantation compared to before-transplantation levels.One patient developed non-ST segment elevation myocardial infarction and treated with percutaneous coronary intervention,another patient developed atrial fibrillation at one year after transplantation.The plasma mRNA expression of SR-B [was reduced (20.44 ± 0.60 vs.23.12 ±0.69,P ＜0.05) while the expression of CD36 mRNA was upregulated(20.91 ±0.35 vs.18.55 ± 0.62,P ＜ 0.05) at 1 year after liver transplantation compare with that of before the transplantation.Similarly,the plasma protein expression of SR-B Ⅰ was reduced (0.21 ± 0.13 vs.0.64 ± 0.28,P ＜ 0.05) while the protein expression of CD36 was upregulated (0.94 ± 0.13 vs.0.42 ± 0.19,P ＜ 0.05) at 1 year after liver transplantation compare with that of before the transplantation.Conclusion Plasma expression changes of SR-B Ⅰ and CD36 might contribute to the dyslipidemia and contribute to the atherosclerosis susceptibility after liver transplantation.
